Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab

IMPORTANCE: Ustekinumab, a monoclonal antibody targeting interleukin 12/23p40 (IL-12/23p40), is effective in the treatment of moderate to severe psoriasis, psoriatic arthritis, and Crohn disease. In 2011, a meta-analysis of randomized clinical trials reported a potential risk of severe cardiovascula...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Dermatol
Main Authors: Poizeau, Florence, Nowak, Emmanuel, Kerbrat, Sandrine, Le Nautout, Béranger, Droitcourt, Catherine, Drici, Milou-Daniel, Sbidian, Emilie, Guillot, Bernard, Bachelez, Hervé, Ait-Oufella, Hafid, Happe, André, Oger, Emmanuel, Dupuy, Alain
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489429/
https://ncbi.nlm.nih.gov/pubmed/32902568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2020.2977
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados